含BA.1以及BA.4/BA.5的二价新冠mRNA疫苗在日本BA.5流行期预防有症状的SARS-CoV-2感染的有效性
Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.
作者信息
Arashiro Takeshi, Arima Yuzo, Kuramochi Jin, Muraoka Hirokazu, Sato Akihiro, Chubachi Kumi, Yanai Atsushi, Arioka Hiroko, Uehara Yuki, Ihara Genei, Kato Yasuyuki, Yanagisawa Naoki, Ueda Akihiro, Kato Hideaki, Oka Hideaki, Nishida Yusuke, Nidaira Yuki, Asami Takahiro, Jinta Torahiko, Nakamura Akira, Oba Kunihiro, Taniyama Daisuke, Yamamoto Kei, Tanaka Katsushi, Ueshima Kankuro, Fuwa Tetsuji, Stucky Ashley, Suzuki Tadaki, Smith Chris, Hibberd Martin, Ariyoshi Koya, Suzuki Motoi
机构信息
Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan.
Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
出版信息
Open Forum Infect Dis. 2023 May 3;10(6):ofad240. doi: 10.1093/ofid/ofad240. eCollection 2023 Jun.
Abstract
In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).
摘要
在日本开展的这项多中心、前瞻性、检测阴性的病例对照研究中，与未接种疫苗相比，含BA.1的二价和含BA.4/BA.5的二价2019冠状病毒病mRNA疫苗在BA.5为主的时期预防有症状感染的有效性较高（分别为65%和76%），与半年多前接种的单价疫苗相比则为中等（合并为46%）。
相似文献
1
Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.
Open Forum Infect Dis. 2023 May 3;10(6):ofad240. doi: 10.1093/ofid/ofad240. eCollection 2023 Jun.
2
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
MMWR Morb Mortal Wkly Rep. 2022 Dec 2;71(48):1526-1530. doi: 10.15585/mmwr.mm7148e1.
3
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):119-124. doi: 10.15585/mmwr.mm7205e1.
4
Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
Clin Infect Dis. 2023 Feb 8;76(3):e108-e115. doi: 10.1093/cid/ciac635.
5
SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
MMWR Morb Mortal Wkly Rep. 2023 Jan 27;72(4):100-106. doi: 10.15585/mmwr.mm7204a4.
6
Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
Expert Rev Vaccines. 2023 Jan-Dec;22(1):288-298. doi: 10.1080/14760584.2023.2188950.
7
Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022.
MMWR Morb Mortal Wkly Rep. 2022 Oct 21;71(42):1327-1334. doi: 10.15585/mmwr.mm7142a3.
8
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
Nat Med. 2023 Jan;29(1):247-257. doi: 10.1038/s41591-022-02092-8. Epub 2022 Oct 20.
9
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
MMWR Morb Mortal Wkly Rep. 2022 Oct 21;71(42):1335-1342. doi: 10.15585/mmwr.mm7142a4.
10
Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
Vaccine. 2023 Mar 24;41(13):2280-2288. doi: 10.1016/j.vaccine.2023.02.062. Epub 2023 Feb 27.
引用本文的文献
1
Experience conducting COVID-19 vaccine effectiveness studies in response to the COVID-19 pandemic in Japan and the Philippines: lessons for future epidemics and potential pandemics.
Western Pac Surveill Response J. 2025 Jun 4;16(2):1-8. doi: 10.5365/wpsar.2025.16.2.1157. eCollection 2025 Apr-Jun.
2
Intensity of public health and social measures are associated with effectiveness of SARS-CoV-2 vaccine in test-negative study.
medRxiv. 2025 May 8:2025.05.08.25327221. doi: 10.1101/2025.05.08.25327221.
3
Efficacy, immunogenicity, and safety of heterologous boosting with a novel chimera Chinese mRNA (RQ3013) SARS-CoV-2 vaccine: A randomized, double-blind, active-controlled trial.
Hum Vaccin Immunother. 2025 Dec;21(1):2502250. doi: 10.1080/21645515.2025.2502250. Epub 2025 May 16.
4
Sociobehavioural factors associated with SARS-CoV-2 infection and COVID-19 vaccine effectiveness against medically attended, symptomatic SARS-CoV-2 infection in the Philippines: a prospective case-control study (FASCINATE-P study).
Western Pac Surveill Response J. 2025 Jan 15;16(1):1-12. doi: 10.5365/wpsar.2025.16.1.1131. eCollection 2025 Jan-Mar.
5
SARS-CoV-2 seroprevalence among healthcare workers in a highly vaccinated Japanese medical center from 2020-2023.
Hum Vaccin Immunother. 2024 Dec 31;20(1):2337984. doi: 10.1080/21645515.2024.2337984. Epub 2024 Apr 15.
6
Relative effectiveness of bivalent COVID-19 vaccine: a systematic review and meta-analysis.
Front Med (Lausanne). 2024 Feb 7;10:1322396. doi: 10.3389/fmed.2023.1322396. eCollection 2023.
7
Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination.
Vaccines (Basel). 2023 Dec 28;12(1):36. doi: 10.3390/vaccines12010036.
8
Effectiveness of Adapted COVID-19 Vaccines and Ability to Establish Herd Immunity against Omicron BA.1 and BA4-5 Variants of SARS-CoV-2.
Vaccines (Basel). 2023 Dec 10;11(12):1836. doi: 10.3390/vaccines11121836.
9
Risk of hospital admission and death from first-ever SARS-CoV-2 infection by age group during the Delta and Omicron periods in British Columbia, Canada.
CMAJ. 2023 Oct 30;195(42):E1427-E1439. doi: 10.1503/cmaj.230721.
10
Bivalent Vaccine Effectiveness Among Adults Aged ≥65 Years During the BA.5-Predominant Period in Japan: The VENUS Study.
Open Forum Infect Dis. 2023 Oct 17;10(10):ofad475. doi: 10.1093/ofid/ofad475. eCollection 2023 Oct.
本文引用的文献
1
National seroepidemiological study of COVID-19 after the initial rollout of vaccines: Before and at the peak of the Omicron-dominant period in Japan.
Influenza Other Respir Viruses. 2023 Feb 1;17(2):e13094. doi: 10.1111/irv.13094. eCollection 2023 Feb.
2
Letter to the editor: Importance of considering high-risk behaviours in COVID-19 vaccine effectiveness estimates with observational studies.
Euro Surveill. 2023 Jan;28(4). doi: 10.2807/1560-7917.ES.2023.28.4.2300034.
3
Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters.
N Engl J Med. 2023 Feb 9;388(6):565-567. doi: 10.1056/NEJMc2213948. Epub 2023 Jan 11.
4
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022.
MMWR Morb Mortal Wkly Rep. 2022 Dec 30;71(5152):1616-1624. doi: 10.15585/mmwr.mm715152e1.
5
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022.
MMWR Morb Mortal Wkly Rep. 2022 Dec 30;71(5152):1625-1630. doi: 10.15585/mmwr.mm715152e2.
6
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
MMWR Morb Mortal Wkly Rep. 2022 Dec 2;71(48):1526-1530. doi: 10.15585/mmwr.mm7148e1.
7
Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2.
N Engl J Med. 2022 Nov 3;387(18):1716-1718. doi: 10.1056/NEJMc2211055. Epub 2022 Oct 12.
8
Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study).
Clin Infect Dis. 2023 Feb 8;76(3):e108-e115. doi: 10.1093/cid/ciac635.
9
Behavioral factors associated with SARS-CoV-2 infection in Japan.
Influenza Other Respir Viruses. 2022 Sep;16(5):952-961. doi: 10.1111/irv.12992. Epub 2022 Apr 26.
10
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.
N Engl J Med. 2021 Jul 8;385(2):187-189. doi: 10.1056/NEJMc2104974. Epub 2021 May 5.
Zotero 插件